In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...

Sana revolutionizes treatments for diabetes, cancer, and autoimmune diseases. SANA has high cash burn and dilution risks. See ...

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...

The Lupus Research Alliance (LRA) is proud to announce the inaugural recipients of the new Targeted Research Program on ...

Century Therapeutics has joined the onslaught of cell therapy biotechs taking hits, discontinuing a phase 1 cancer study to ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Treatment of B-cell acute lymphoblastic leukemia has improved thanks to CAR T therapies, but relapse is still very common. An ...

WELLESLEY, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced that members of its executive team will participate at the 24 th Annual Needham Healthcare ...

The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers ...